Literature DB >> 10608478

Undertreatment of hypertension in community-dwelling older adults: a drug-utilization study in Dicomano, Italy.

M Di Bari1, F Salti, M Nardi, M Pahor, C De Fusco, E Tonon, A Ungar, R Pini, G Masotti, N Marchionni.   

Abstract

OBJECTIVE: To define: (1) the prevalence of and (2) factors associated with undertreatment of hypertension in older persons; and (3) the prevalence of specific drug regimens and reasons for their selection. PARTICIPANTS: Cross-sectional survey of persons aged > or =65 years living in Dicomano, Italy. MAIN OUTCOME MEASURES: Prevalence of untreated and uncontrolled hypertension, both defined on the basis of two blood pressure (BP) cut-off points (> or =140/90 and > or =160/90 mm Hg) and of the presence of pharmacological treatment Predictors of undertreatment were analysed for the higher BP cut-off only.
RESULTS: Five hundred of 692 (72.3%) and 380/692 (54.9%) participants met the 140/90 and the 160/90 mm Hg BP criterion, respectively. Of the latter, 162 (42.6%) were untreated, 119 (31.3%) had uncontrolled and 99 (26.1%) controlled hypertension. Women [odds ratio (OR), 0.4; 95% confidence interval (CI), 0.2-0.7], participants with coronary artery disease (CAD) (OR, 0.2; 95% CI, 0.1-0.6), stroke (OR, 0.3; 95% CI, 0.1-0.7), and preserved cognitive status (Mini Mental State Examination score >21: 0.3; 95% CI, 0.2-0.7) were more frequently treated. Uncontrolled hypertension was less likely in women (OR, 0.5; 95% CI, 0.3-1.0) and CAD patients (OR, 0.3; 95% CI, 0.1-0.7). Angiotensin converting enzyme (ACE)-inhibitors (55%), calcium (Ca)-antagonists (31%) and diuretics (20%) were the drugs most commonly prescribed. ACE-inhibitors were preferred, and diuretics rarely used, in diabetic subjects. Ca-antagonists were used mostly in CAD participants.
CONCLUSIONS: Hypertension is undertreated in the majority of noninstitutionalized older adults, especially in men with impaired cognition and no vascular disease. Drug regimens are mostly based on ACE-inhibitors and Ca-antagonists, as a result of associated clinical conditions, requiring individualized treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608478     DOI: 10.1097/00004872-199917110-00018

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Renin-angiotensin-aldosterone system blockade is safe and effective in elderly hypertensive patients with and without impaired renal function.

Authors:  Claudio Ferri; Livia Ferri
Journal:  High Blood Press Cardiovasc Prev       Date:  2012-12

2.  Predictors of resistant hypertension in an unselected sample of an adult male population in Italy.

Authors:  Antonio Barbato; Ferruccio Galletti; Roberto Iacone; Francesco P Cappuccio; Giovanni Rossi; Renato Ippolito; Antonella Venezia; Eduardo Farinaro; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2011-03-10       Impact factor: 3.397

Review 3.  Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Emanuele Bobbio; Paola Paparello; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

4.  Changing prediction of mortality by systolic blood pressure with increasing age: the Rotterdam study.

Authors:  J W Blom; W de Ruijter; J C M Witteman; W J J Assendelft; M M B Breteler; A Hofman; J Gussekloo
Journal:  Age (Dordr)       Date:  2011-12-15

5.  Gaps between hypertension treatment guidelines and clinical practice in Japan: Baseline survey results from Fukushima Research of Hypertension (FRESH).

Authors:  Hirohide Yokokawa; Aya Goto; Hironobu Sanada; Tsuyoshi Watanabe; Seiji Yasumura
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-06       Impact factor: 3.738

6.  Generalizability of guidelines and physicians' adherence. Case study on the Sixth Joint National Commitee's guidelines on hypertension.

Authors:  Claudio Pedone; Kate L Lapane
Journal:  BMC Public Health       Date:  2003-07-21       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.